Impact of IFNL4-ΔG genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals

被引：5
|
作者：
Backus, Lisa I. [1 ]
Shahoumian, Troy A. [1 ]
Belperio, Pamela S. [1 ]
Winters, Mark [2 ]
Prokunina-Olsson, Ludmila [3 ]
O'Brien, Thomas R. [3 ]
Holodniy, Mark [2 ,4 ]
机构：
[1] Populat Hlth Serv, Dept Vet Affairs, Palo Alto, CA 94304 USA
[2] Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[4] Off Publ Hlth Surveillance & Res, Dept Vet Affairs, Palo Alto, CA 94304 USA
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2018年 / 92卷 / 01期
基金：
美国国家卫生研究院;
关键词：
IFNL4; SVR; hepatitis C virus; DAA therapy; Veterans; HCV CLEARANCE; VIRUS; IFNL4; ASSOCIATION; INFECTION; RIBAVIRIN; VARIANTS; THERAPY; IL28B;
D O I：
10.1016/j.diagmicrobio.2018.04.004
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
In direct acting antiviral (DAA)-treated HCV genotype 1, the sustained virologic response rate with the Delta G/Delta G genotype of IFNL4 rs368234815 (86.8%) was significantly lower than with Delta G/TT (95.9%, P = 0.03) or TT/IT (98.6%, P = 0.01). The SVR odds ratio for Delta G/Delta G compared to TT/TT was 0.10 (P = 0.03). IFNL4 genotype might predict DAA-response. Published by Elsevier Inc.
引用
收藏
页码：34 / 36
页数：3
相关论文
共 50 条
  • [1] IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin
    Meissner, Eric G.
    Bon, Dimitra
    Prokunina-Olsson, Ludmila
    Tang, Wei
    Masur, Henry
    O'Brien, Thomas R.
    Herrmann, Eva
    Kottilil, Shyamasundaran
    Osinusi, Anuoluwapo
    JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (11) : 1700 - 1704
  • [2] Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-ΔG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy
    Emmanuel, Benjamin
    El-Kamary, Samer S.
    Magder, Laurence S.
    Stafford, Kristen A.
    Charurat, Man E.
    Chairez, Cheryl
    McLaughlin, Mary
    Hadigan, Colleen
    Prokunina-Olsson, Ludmila
    O'Brien, Thomas R.
    Masur, Henry
    Kottilil, Shyam
    JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (01) : 102 - 109
  • [3] Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals
    Benetti, Fabia
    de Araujo, Alexandre
    de Maman Junior, Italo
    Cheinquer, Cristina Coelho Borges
    Wolff, Fernando Herz
    Cheinquer, Hugo
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2024, 68
  • [4] Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients
    Pedergnana, Vincent
    Irving, William L.
    Barnes, Eleanor
    McLauchlan, John
    Spencer, Chris C. A.
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2019, 39 (10) : 642 - 649
  • [5] Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
    Karino, Yoshiyasu
    Toyota, Joji
    Ikeda, Kenji
    Suzuki, Fumitaka
    Chayama, Kazuaki
    Kawakami, Yoshiiku
    Ishikawa, Hiroki
    Watanabe, Hideaki
    Hernandez, Dennis
    Yu, Fei
    McPhee, Fiona
    Kumada, Hiromitsu
    JOURNAL OF HEPATOLOGY, 2013, 58 (04) : 646 - 654
  • [6] Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals
    Bonacci, Martin
    Lens, Sabela
    Londono, Maria-Carlota
    Marino, Zoe
    Cid, Maria C.
    Ramos-Casals, Manuel
    Mara Sanchez-Tapias, Jose
    Forns, Xavier
    Hernandez-Rodriguez, Jose
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (04) : 575 - +
  • [7] Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey
    Sahin, Ahmet
    Akay, Ozlem
    ANNALS OF SAUDI MEDICINE, 2023, 43 (05) : 308 - 314
  • [8] Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection
    Ohya, Kazuki
    Kawaoka, Tomokazu
    Imamura, Michio
    Morio, Kei
    Nakahara, Takashi
    Murakami, Eisuke
    Yamauchi, Masami
    Hiramatsu, Akira
    Tsuge, Masataka
    Aikata, Hiroshi
    Chayama, Kazuaki
    INTERNAL MEDICINE, 2020, 59 (07) : 941 - 944
  • [9] Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
    Congly, S. E.
    Lee, S. S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (08) : 983 - 984
  • [10] Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection
    Nakajima, Tomoaki
    Karino, Yoshiyasu
    Hige, Shuhei
    Suii, Hirokazu
    Tatsumi, Ryoji
    Yamaguchi, Masakatsu
    Arakawa, Tomohiro
    Kuwata, Yasuaki
    Toyota, Joji
    ANNALS OF HEPATOLOGY, 2022, 27 (01)
12345